Organon. Organon represents and warrants that it has all requisite power and authority to execute, deliver, and perform this Agreement and to consummate the transactions contemplated hereby. The execution, delivery, and performance of this Agreement and the consummation by it of the actions contemplated hereby will be, upon delivery, duly and validly executed and delivered by Organon and will constitute its legal, valid, and binding obligation.
Organon. Xxxxxxx X. Xxxxx Xxxx Xxxxx LLP 136 Main Street, Suite 000 Xxxxxxxxx Xxxxxxxxx Xxxxxxx Princeton, NJ 08540 xxxxxx@xxxxxxxxx.xxx Phone: 000-000-0000 -and- Xxxxxxx X. Xxxxxxx Xxxxx Xxxx LLP One Metropolitan Square 000 Xxxxx Xxxxxxxx, Xxxxx 0000 Xx. Xxxxx, XX 00000-0000 xxxxxxxxx@xxxxxxxxx.xxx Phone: 000-000-0000
Organon s/ Xxxxx Xxxxxxxxx By: Xxxxx Xxxxxxxxx, Ph.D. Name: Title: Sr. VP, Worldwide Licensing & Knowledge Management Address: 000 X. XXXXXXX AVE. RAILWAY INS 07065 Tel: 000-000-0000 Fax: 000-000-0000 email: XXXXX.XXXXXXXXX@XXXXX.XXX XXXXXXX XXXXXXXXX M.D. ADDRESS: TEL: FAX: EMAIL:
Organon. Xxxxx, Xxxx Xxxxxx, Xxxxxxx X. and Xxxxx K (JTWROS) Beam, Xxxxxx X. Xxxxx, Xxxxxx X. Xxxxxxx, Xxxxxxx Xxxx Xxxx, Xxxxx Xxxxxxx, Xxxxxxx and Xxxxxx (JTWROS) Xxxxxxxx, Xxxxxxx X. Conan, Xxxxx Xxxxx, Xxx X. Xxxxx, Xxxxx Xxxx, Xxxxxx Duty, Xxxxx X. Xxxxxx, Xxxxxxx X. Xxxxxxxx, Xxxxxx XXX (Xxxxx, Xxxx & Xxxxx Inc C/F) Xxxxxxx, Xxxxxxx and Xxxxx Xxxxxxxxxx, Xxxxxxx Xxx, L. Xxxx Xxxxx, Xxxxx X. and Xxxxxxxx X. (JTWROS) Xxxxxx, Xxxxx X. XXX Xxxxx, Xxxxxxxx Xxxxxxx, Xxxxxxx X. Xxxxxxxx, Xxxxxxxxxxx X. Xxxxxxxx, Xxxxxxx X. Xxxxxxxx, Xxxxxx X., Jr. and Xxxxxxx X. (JTWROS) Xxxxxx, Xxxxxx X. Xxxxx, Xxxxx X. Xxxxxxx, Xxxxxx 0. and Xxxxx X. (JTWROS) Xxxxxx, Xxxxxxx X. Trust U/A/D 9/25/09, Xxxxxxx X. Xxxxxx Trustee Xxxxxxxxx, Xxx X. and Xxxxx X. (JTWROS) Xxxx, Xxxxx X. Xxxxxxxx, Xxxxxxx X. Xxxxxx, Xxxxxxx Xxxxxxxx, Xxxxxxx X. XxXxxxxx, Xxxxx X. Xxxxxx, Xxxxx XXX (Xxxxxx X. Xxxxx & Co., Inc. TTEE, FBO Xxxxx Xxxxxx XXX Acct # 6144 2867) Muckenhin, Xxxx X. Xxxxxx, Xxx X. X'Xxxxx, Xxxxx Xxxxxx, Xxxxxx X. Xxxxx, Xxxxxx Xxxx Xxxxxxxxxx, Xxxxxxx X. and Xxxxxxxxx X. (JTWROS) Xxxxxxxxxx, Xxxx and Xxxxxxx, Xxxxxxxxxx (jtwros) Xxxx, Xxxxxxx X. and Xxxxxxxxx X. Xxxx, Xxxxxxx Xxxxxxxxxx, Xxxx X. Xxxxxx, Xxxxxxx X. Xxxxx, Xxxxxx X. Xxxxxx, Xxxxxx X. Xxxxxxx, Xxxxxx Xxxxx, Xxxxxx X. Xxxxxx, Xxxx X. XXX (Xxxxxx, Xxxx & Xxxxx Inc. C/F) Xxxxxxx, Xxxxxx X. Xxxxxx, Xxxxxxx X. Xxxxx, Xxxxxxx X. and Xxxxxxx X. (JTWROS) Xxxxxxxx, Xxxx X. Xxxxxxx, Xxxxxxx X. and Xxxxxxx, Xxxxx X. Xxxxxxx, TTEE fbo The Xxxxxxx Family Revocable Trust dtd 8/13/07 Xxxxxxx, Xxxxxxx X. Xxxxxxxx, Xxxxxxx Xxxxx, Xxxxxx X. Xxxxxx, Xxxxxxx, III and Xxxxxx, Xxxxxxxx Xxxxx XXXXXX of The Xxxxxx Family Restated Living Trust UTA dtd 04/2004 Xxxxxxxx, Xxxxx X. Xxxxxxxxxx, Xxxxx X. and Xxxxxxx X. (JTWROS) Zar, Xxxxx X. Xxxxxxxx, Xxxxxx X. Xxxxxxxx, Xxxxx Xxxxxxxx, Xxxxx Xxxxxxxx, Xxxxxx Xxxxxx Xx., Xxxx X. Matter, Xx. Xxxxxxx and Xxxxx (JTWROS) Xxxxxx, Xxxxxx Xxxxxxxx and Xxxxxxx (JTWROS) Xxxx, Xxxxxxx and Xxxxx (JTWROS) Xxxxxxx, Xxxxx Craig, Xxx X. Xxxx, Xxxxxxx X. Xxxxxxxx, Xxxxxxx Xxxxxxxx, Xxxxxxx X., MD and Xxxx X. Variety Investments Limited Xxxxxxxx, Xxxxxxxxx X. XXX (Xxxxx Xxxx & Xxxxx Inc. CIF) Xxxxxxxx, Xx. Xxxx X. Jones, Xxx. A. Xxxxx, Xxxxxxxxxxx X. Xxxxxx, Xxx X. Xxxxxx, Xxxxxx and Xxxxxxx (JTWROS) Xxxxxxx, Xxxxxxx Xxxx, Xxxxx X. XXX (Xxxxxx Xxxx & Xxxxx Inc. C/F Xxxxx X. Xxxx R/O XXX) Xxxxxx, Xxxxxx Xxxxx, Xxxx X. Xxxxxxx, Xxxxx X. Xxxxx, Xxxxx X. and Xxxxx X. (JTWROS) Xxxx, Xxxxxxx X. and Xxxxxxx X. (JTWROS) Xxx, ...
Organon. By: /s/ Frans Lxxxxxxxxxx By: /s/ Wim Schxxxxxx Name: Frans Lxxxxxxxxxx Xxxx: Wim Schxxxxxx Xxxxx: Director Marketing & Sales API/BT Title: Marketing Manager Chemical Products Date: 21-7-2011 Date: 21-7-2011 Biodel Biodel By: /s/ Gerard X. Xxxxxx By: /s/ Paul Baxxxx Name: Gerard X. Xxxxxx Xxxx: Paul Baxxxx Xxxxx: CFO Title: Secretary Date: 7/25/11 Date: 7/25/11 Exhibit A to Supply Agreement Amendment
Organon. NV Organon develops and produces pharmaceutical products in fields such as gynaecology, psychiatry, athero-thrombosis, and auto-immune diseases. The company employs more than 11,500 employees worldwide. The company invests over 17 percent of its sales income in its drug discovery and development programmes. NV Organon is one of the pharmaceutical business units of Akzo Nobel. Akzo Nobel, based in the Netherlands, serves customers throughout the world with healthcare products, coatings, and chemicals. The company currently employs approximately 68,000 people in almost 75 countries. Consolidated sales for 1999 will total about EUR 12 billion (NLG 26 billion). LIGAND PHARMACEUTICALS INCORPORATED Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men's and women's hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. In addition to the recently approved Targretin(R) capsules, Ligand had two drugs approved during 1999 for marketing in the U.S. -- ONTAK(R) and Panretin(R) gel -- that are being marketed through its specialty cancer and HIV-center sales force in the U.S. Targretin(R) gel is currently under review by the FDA for marketing approval in the U.S., and two additional oncology-related products -- Morphelan(TM) (licensed from Elan) and Panretin(R) capsules -- are in late-stage development. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IR) and Signal Transducers and Activators of Transcription (STATs). This news release may contain certain forward-looking statements by Ligand and actual results could differ materially from those described as a result of factors outside of the control of Ligand. There can be no assurance that (a) the collaborative arrangement will be successful or continued, (b) Ligand will receive any further reimbursement amounts for the prior development of its technology or any milestone payments for the discovery and/or development of any compounds, (c) any compounds will be discovered and/or be deemed
Organon. Organon represents and warrants on its own behalf and on behalf of its Affiliates that: (i) it has the legal right and authority to enter into this Agreement and to perform all of its obligations hereunder; (ii) when executed by both parties, this Agreement will constitute the valid and legally binding obligation of Organon and shall be enforceable against Organon in accordance with its terms; and (iii) that it has not previously granted, and during the term of this Agreement will not knowingly make any commitment of or grant any rights which in any material way conflict with the rights and licenses granted herein.
Organon. Organon agrees to indemnify, defend and hold Pharmacopeia and its Affiliates and their directors, officers, employees and agents (the "Pharmacopeia Indemnitees") harmless from and against any losses, costs, claims, damages, liabilities or expense (including without limitation, fees and disbursements of counsel incurred by the Pharmacopeia Indemnitee in any action or proceeding between Organon and the Pharmacopeia Indemnitee and the Pharmacopeia Indemnitee and any third party or otherwise) (collectively, "Liabilities") arising out of or in connection with third party claims relating to: (i) any Agreement Products or Transferred Technology Products developed, manufactured, used, sold or otherwise distributed by or on behalf of Organon, its Affiliates, Sublicensees or other designees (including, without limitation, third-party product liability claims); (ii) Organon and its Affiliates performance of the Research Program; or (iii) any breach by Organon of its representations and warranties made in this Agreement, except, in each case, to the extent such Liabilities result from the gross negligence or intentional misconduct of Pharmacopeia.
Organon. By: Xxxxx Xxxxxxxxx, Ph.D. Title: Sr. VP, Worldwide Licensing and Knowledge Management XXXXXXX XXXXXXXXX, XX., M.D. AMENDMENT NO. 1 TO API REGISTRATION RIGHTS AGREEMENT AMENDMENT NO. 1 TO API REGISTRATION RIGHTS AGREEMENT
Organon. THIS DEVELOPMENT AND LICENSE OPTION AGREEMENT (the "Agreement") is entered into by and between CIMA LABS INC., a Delaware corporation ("CIMA") and N.V. ORGANON, a Dutch corporation (Organon), on this 2nd day of December, 1998 (the "EFFECTIVE DATE").
